MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy

Seminars in Immunology - Tập 47 - Trang 101391 - 2020
Shailendra K. Gautam1, Sushil Kumar1, Vi Dam2, Dario Ghersi2, Maneesh Jain1,3, Surinder K. Batra1,4,5,6
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
2School of Interdisciplinary Informatics, University of Nebraska Omaha, NE, 68182, USA
3Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA
4Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, 68198, USA
5Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA
6Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE, 68198, USA

Tài liệu tham khảo

Siegel, 2019, Cancer statistics, 2019, CA Cancer J. Clin., 69, 7, 10.3322/caac.21551

Stathis, 2010, Advanced pancreatic carcinoma: current treatment and future challenges, Nat. Rev. Clin. Oncol., 7, 163, 10.1038/nrclinonc.2009.236

Werner, 2013, Advanced-stage pancreatic cancer: therapy options, Nat. Rev. Clin. Oncol., 10, 323, 10.1038/nrclinonc.2013.66

Neoptolemos, 2018, Therapeutic developments in pancreatic cancer: current and future perspectives, Nat. Rev. Gastroenterol. Hepatol., 15, 333, 10.1038/s41575-018-0005-x

Wang, 2010, Pancreatic cancer: understanding and overcoming chemoresistance, Nat. Rev. Gastroenterol. Hepatol., 8, 27, 10.1038/nrgastro.2010.188

Gbolahan, 2019, Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study, BMC Cancer, 19, 468, 10.1186/s12885-019-5630-4

Looi, 2019, Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment, J. Exp. Clin. Cancer Res., 38, 162, 10.1186/s13046-019-1153-8

Glitza Oliva, 2018, Immunotherapy for melanoma, Adv. Exp. Med. Biol., 995, 43, 10.1007/978-3-030-02505-2_2

Banerjee, 2018, Emerging trends in the immunotherapy of pancreatic cancer, Cancer Lett., 417, 35, 10.1016/j.canlet.2017.12.012

Wu, 2019, Current status of immunotherapies for treating pancreatic cancer, Curr. Oncol. Rep., 21, 60, 10.1007/s11912-019-0811-5

Taylor-Papadimitriou, 2018, Latest developments in MUC1 immunotherapy, Biochem. Soc. Trans., 46, 659, 10.1042/BST20170400

Blando, 2019, Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer, Proc. Natl. Acad. Sci. U. S. A., 116, 1692, 10.1073/pnas.1811067116

Hilmi, 2018, Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?, World J. Gastroenterol., 24, 2137, 10.3748/wjg.v24.i20.2137

Protti, 2013, Immune infiltrates as predictive markers of survival in pancreatic cancer patients, Front. Physiol., 4

Fukunaga, 2004, CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma, Pancreas, 28, e26, 10.1097/00006676-200401000-00023

Murakami, 2019, Role of the tumor microenvironment in pancreatic cancer, Ann. Gastroenterol. Surg., 3, 130, 10.1002/ags3.12225

Liu, 2019, Cancer-associated fibroblasts build and secure the tumor microenvironment, Front. Cell Dev. Biol., 7, 60, 10.3389/fcell.2019.00060

Wei, 2018, Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer, Cell Death Dis., 9, 1065, 10.1038/s41419-018-1104-x

Öhlund, 2017, Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer, J. Exp. Med., 214, 579, 10.1084/jem.20162024

Harper, 2014, Regulation of the anti-tumour immune response by cancer-associated fibroblasts, Semin. Cancer Biol., 25, 69, 10.1016/j.semcancer.2013.12.005

Fukunaga, 2004, CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma, Pancreas, 28, e26, 10.1097/00006676-200401000-00023

Crespo, 2013, T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, Curr. Opin. Immunol., 25, 214, 10.1016/j.coi.2012.12.003

Bauer, 2016, Prevailing over T cell exhaustion: new developments in the immunotherapy of pancreatic cancer, Cancer Lett., 381, 259, 10.1016/j.canlet.2016.02.057

Kabacaoglu, 2018, Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options, Front. Immunol., 9, 1878, 10.3389/fimmu.2018.01878

Soares, 2015, PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors, J. Immunother., 38, 1, 10.1097/CJI.0000000000000062

Winograd, 2015, Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma, Cancer Immunol. Res., 3, 399, 10.1158/2326-6066.CIR-14-0215

Gao, 2019, Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer, Br. J. Cancer, 120, 88, 10.1038/s41416-018-0298-0

Balachandran, 2019, Broadening the impact of immunotherapy to pancreatic Cancer: challenges and opportunities, Gastroenterology, 156, 2056, 10.1053/j.gastro.2018.12.038

Matsui, 2018, Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies, Expert Rev. Anticancer Ther., 18, 1205, 10.1080/14737140.2018.1531707

Lutz, 2014, Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation, Cancer Immunol. Res., 2, 616, 10.1158/2326-6066.CIR-14-0027

Le, 2015, Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer, J. Clin. Oncol., 33, 1325, 10.1200/JCO.2014.57.4244

Kinkead, 2018, Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer, JCI Insight, 3, 10.1172/jci.insight.122857

Seery, 2019, NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer, J. Clin. Oncol., 37, TPS463, 10.1200/JCO.2019.37.4_suppl.TPS463

Cannon, 2019, The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy, Immunotherapy, 11, 75, 10.2217/imt-2018-0129

Koido, 2017, Significance of Wilms’ tumor 1 antigen as a cancer vaccine for pancreatic cancer, Discov. Med., 24, 41

Hanada, 2019, Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines, Hum. Vaccin. Immunother., 15, 397, 10.1080/21645515.2018.1524238

Zaidi, 2019, Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4(+) effector T cell infiltration into murine pancreatic tumors, Ann. N. Y. Acad. Sci., 1445, 62, 10.1111/nyas.14049

Hardwick, 2014, p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses, Clin. Cancer Res., 20, 4459, 10.1158/1078-0432.CCR-13-3361

Chen, 2019, Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors, J. Clin. Invest., 130

Kaur, 2013, Mucins in pancreatic cancer and its microenvironment, Nat. Rev. Gastroenterol. Hepatol., 10, 607, 10.1038/nrgastro.2013.120

Jonckheere, 2010, Mucins and pancreatic cancer, Cancers, 2, 1794, 10.3390/cancers2041794

Rachagani, 2012, Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy, J. Hematol. Oncol., 5, 68, 10.1186/1756-8722-5-68

Kufe, 2009, Mucins in cancer: function, prognosis and therapy, nature reviews, Cancer, 9, 874

Kaur, 2017, A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer: a multicenter study, Am. J. Gastroenterol., 112, 172, 10.1038/ajg.2016.482

Wang, 2011, Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering, Anal. Chem., 83, 2554, 10.1021/ac102829b

Gold, 2006, New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis, J. Clin. Oncol., 24, 252, 10.1200/JCO.2005.02.8282

Kohlgraf, 2003, Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line, Cancer Res., 63, 5011

Satoh, 2000, Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule, Int. J. Cancer, 88, 507, 10.1002/1097-0215(20001115)88:4<507::AID-IJC1>3.0.CO;2-0

Roy, 2011, MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition, Oncogene, 30, 1449, 10.1038/onc.2010.526

Chaturvedi, 2008, MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells, Cancer Res., 68, 2065, 10.1158/0008-5472.CAN-07-6041

Moniaux, 2007, Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells, Br. J. Cancer, 97, 345, 10.1038/sj.bjc.6603868

Das, 2015, Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy, Cancer Res., 75, 4669, 10.1158/0008-5472.CAN-15-1050

Chen, 2013, Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation, Sci. Rep., 3, 1870, 10.1038/srep01870

Muniyan, 2016, MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism, Genes Cancer, 7, 110, 10.18632/genesandcancer.104

Haridas, 2011, Pathobiological implications of MUC16 expression in pancreatic cancer, PLoS One, 6, 10.1371/journal.pone.0026839

Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462

Matsui, 2017, Postoperative adjuvant therapy for resectable pancreatic cancer with gemcitabine and adoptive immunotherapy, Pancreas, 46, 994, 10.1097/MPA.0000000000000880

Kato, 2014, [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers], Gan to kagaku ryoho, Cancer Chemother., 41, 1280

Mehla, 2018, Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors, Cancer Immunol. Immunother., 67, 445, 10.1007/s00262-017-2095-7

Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462

Gautam, 2017, MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma, Expert Opin. Ther. Targets, 21, 657, 10.1080/14728222.2017.1323880

Saitou, 2005, MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas, J. Clin. Pathol., 58, 845, 10.1136/jcp.2004.023572

Swartz, 2002, MUC4 expression increases progressively in pancreatic intraepithelial neoplasia, Am. J. Clin. Pathol., 117, 791, 10.1309/7Y7N-M1WM-R0YK-M2VA

Jahan, 2018, Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-beta1/FAK/ERK pathway, Biochim. Biophys. Acta Mol. Basis Dis., 1864, 2538, 10.1016/j.bbadis.2018.05.008

Pai, 2016, The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma, Mol. Oncol., 10, 224, 10.1016/j.molonc.2015.10.005

Senapati, 2011, Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer, Clin. Cancer Res., 17, 267, 10.1158/1078-0432.CCR-10-1937

Kumar, 2017, Genetic variants of mucins: unexplored conundrum, Carcinogenesis, 38, 671

Urey, 2017, Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine, Scand. J. Gastroenterol., 52, 595, 10.1080/00365521.2017.1290134

Ponnusamy, 2011, MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells, J. Ovarian Res., 4, 7, 10.1186/1757-2215-4-7

Singh, 2004, Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis, Cancer Res., 64, 622, 10.1158/0008-5472.CAN-03-2636

Bafna, 2009, Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin, Br. J. Cancer, 101, 1155, 10.1038/sj.bjc.6605285

Wei, 2008, Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses, Cancer Biother. Radiopharm., 23, 121, 10.1089/cbr.2007.0427

Wu, 2009, Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy, Immunopharmacol. Immunotoxicol., 31, 468, 10.1080/08923970902795203

Chen, 2013, Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA, Vaccine, 31, 4585, 10.1016/j.vaccine.2013.07.055

Cai, 2015, Antibody induction directed against the tumor-associated MUC4 glycoprotein, ChemBioChem, 16, 959, 10.1002/cbic.201402689

Banerjee, 2019, Amphiphilic polyanhydride-based recombinant MUC4βnanovaccine activates dendritic cells, Genes Cancer, 10, 52, 10.18632/genesandcancer.189

Cafri, 2019, Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients, Nat. Commun., 10, 449, 10.1038/s41467-019-08304-z

Kinkead, 2018, Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer, JCI Insight, 3, 10.1172/jci.insight.122857

Jiang, 2019, Tumor neoantigens: from basic research to clinical applications, J. Hematol. Oncol., 12, 93, 10.1186/s13045-019-0787-5

Leao, 2008, Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma, Clin. Transl. Sci., 1, 228, 10.1111/j.1752-8062.2008.00070.x

Koşaloğlu-Yalçın, 2018, Predicting T cell recognition of MHC class I restricted neoepitopes, Oncoimmunology, 7, e1492508, 10.1080/2162402X.2018.1492508

Smith, 2019, Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes, Cancer Immunol. Res., 10.1158/2326-6066.CIR-19-0155

Quandt, 2018, Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses, Oncoimmunology, 7, e1500671, 10.1080/2162402X.2018.1500671

Raphael, 2017, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell, 32, 10.1016/j.ccell.2017.07.007

Larsen, 2007, Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction, BMC Bioinformatics, 8, 424, 10.1186/1471-2105-8-424

Zerbino, 2018, Ensembl 2018, Nucleic Acids Res., 46, D754, 10.1093/nar/gkx1098

Jain, 2011, Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer, PLoS One, 6, 10.1371/journal.pone.0023344

Moniaux, 2004, Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans, J. Histochem. Cytochem., 52, 253, 10.1177/002215540405200213

Thông tin
Thông tin xuất bản

Seminars in Immunology

Tập 47

101391

Thông tin tác giả